Avalo Therapeutics Q3 Net Loss Narrows 38% to $18.95 Million

Bitget2026/11/05 12:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Avalo Therapeutics’ third-quarter 2026 net loss narrowed 38% year over year to $18.95 million.
Cash, cash equivalents and investments totaled $462.8 million at September 30, 2026, expected to fund operations into 2029.
Abdakibart’s Phase 3 program in hidradenitis suppurativa is planned to start in the first half of 2027.
An Investigational New Drug submission for AVTX-010, a long-acting anti-IL-1β antibody, is anticipated in the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870829) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Avalo Therapeutics Q3 Net Loss Narrows 38% to $18.95 Million

You may also like

Crypto prices